Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. The standard treatment for advanced stage is the combination of optimal debulking surgery and platinum-based chemotherapy. Nevertheless, recurrence is frequent (around 70%) and prognosis is globally poor. New the...

Full description

Bibliographic Details
Main Authors: Gloria Mittica, Sofia Genta, Massimo Aglietta, Giorgio Valabrega
Format: Article
Language:English
Published: MDPI AG 2016-07-01
Series:International Journal of Molecular Sciences
Subjects:
ovarian cancer
immune checkpoint inhibitor
ipilimumab
nivolumab
pembrolizumab
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
programmed cell death-1 (PD-1)
programmed cell death ligand-1 (PD-L1)
tumor infiltrating lymphocytes (TILs)
Online Access:http://www.mdpi.com/1422-0067/17/7/1169

Internet

http://www.mdpi.com/1422-0067/17/7/1169

Similar Items